FI4349406T3 - 6-karboksi-2-(3,5-dikloorifenyyli)-bentsoksatsolin kiteisiä kiinteitä muotoja käytettäväksi lääkkeenä - Google Patents

6-karboksi-2-(3,5-dikloorifenyyli)-bentsoksatsolin kiteisiä kiinteitä muotoja käytettäväksi lääkkeenä

Info

Publication number
FI4349406T3
FI4349406T3 FIEP24152053.5T FI24152053T FI4349406T3 FI 4349406 T3 FI4349406 T3 FI 4349406T3 FI 24152053 T FI24152053 T FI 24152053T FI 4349406 T3 FI4349406 T3 FI 4349406T3
Authority
FI
Finland
Prior art keywords
oral dosage
dosage form
benzoxazole
dichlorophenyl
carboxy
Prior art date
Application number
FIEP24152053.5T
Other languages
English (en)
Finnish (fi)
Inventor
Kevin Paul Girard
Andrew J Jensen
Kris Nicole Jones
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54199901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4349406(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of FI4349406T3 publication Critical patent/FI4349406T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
FIEP24152053.5T 2014-09-08 2015-08-31 6-karboksi-2-(3,5-dikloorifenyyli)-bentsoksatsolin kiteisiä kiinteitä muotoja käytettäväksi lääkkeenä FI4349406T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462047614P 2014-09-08 2014-09-08
US201562203953P 2015-08-12 2015-08-12

Publications (1)

Publication Number Publication Date
FI4349406T3 true FI4349406T3 (fi) 2026-02-04

Family

ID=54199901

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP24152053.5T FI4349406T3 (fi) 2014-09-08 2015-08-31 6-karboksi-2-(3,5-dikloorifenyyli)-bentsoksatsolin kiteisiä kiinteitä muotoja käytettäväksi lääkkeenä
FIEP21203965.5T FI3977993T3 (fi) 2014-09-08 2015-08-31 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP21203965.5T FI3977993T3 (fi) 2014-09-08 2015-08-31 6-karboksi-2-(3,5-dikloorifenyyli)bentsoksatsolin kiteiset kiinteät muodot käytettäväksi lääkkeenä

Country Status (24)

Country Link
US (1) US9770441B1 (https=)
EP (3) EP4349406B1 (https=)
JP (5) JP2016065042A (https=)
KR (1) KR102004059B1 (https=)
CN (2) CN106715405A (https=)
AU (1) AU2015313875B2 (https=)
BR (1) BR112017003421B1 (https=)
CA (1) CA2903194A1 (https=)
CY (1) CY1124843T1 (https=)
DK (2) DK3977993T3 (https=)
ES (3) ES2901785T3 (https=)
FI (2) FI4349406T3 (https=)
HR (1) HRP20211834T1 (https=)
HU (2) HUE056583T2 (https=)
IL (1) IL251037B1 (https=)
LT (1) LT3191461T (https=)
MX (1) MX374012B (https=)
PL (3) PL3977993T3 (https=)
PT (3) PT4349406T (https=)
RS (1) RS62634B1 (https=)
SG (1) SG11201700958YA (https=)
SI (3) SI3977993T1 (https=)
TW (1) TWI644902B (https=)
WO (1) WO2016038500A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
ES2991081T3 (es) 2019-04-11 2024-12-02 Inke Sa Procedimiento para preparar 2-(3,5-diclorofenil)-6-benzoxazolcarboxilato de 1-desoxi-1-metilamino-D-glucitol
EP3969443B1 (en) 2019-05-16 2024-11-20 Teva Pharmaceuticals International GmbH Solid state forms of tafamidis and salts thereof
WO2021001858A1 (en) * 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
JP2023503833A (ja) * 2019-11-15 2023-02-01 ▲蘇▼州科睿思制▲葯▼有限公司 タファミジスの結晶形及びその調製方法及びその使用
MX2022007787A (es) 2019-12-20 2022-07-19 Pfizer Ireland Pharmaceuticals Proceso eficiente para elaborar derivados de 6-carboxi-benzoxazol.
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
WO2021232619A1 (zh) * 2020-05-19 2021-11-25 苏州科睿思制药有限公司 一种他发米帝司游离酸的晶型及其制备方法和用途
WO2022009221A1 (en) * 2020-07-04 2022-01-13 Nuray Chemicals Private Limited Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof
WO2022084790A1 (en) * 2020-10-19 2022-04-28 Glenmark Life Sciences Limited Process for preparation of tafamidis and salts thereof
WO2022107166A1 (en) * 2020-11-20 2022-05-27 Natco Pharma Limited Novel crystalline form of tafamidis and its process thereof
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN114907283B (zh) * 2021-02-07 2025-01-28 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
CN114989106A (zh) * 2021-02-09 2022-09-02 齐鲁制药有限公司 氯苯唑酸的新晶型及其制备方法
EP4083027A1 (en) 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
US20250042864A1 (en) 2021-11-17 2025-02-06 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
KR20250036933A (ko) 2022-07-28 2025-03-14 화이자 인코포레이티드 타파미디스 약학 조성물
EP4605382A1 (en) * 2022-10-17 2025-08-27 Biophore India Pharmaceuticals Pvt. Ltd. A process for the preparation of crystalline form of tafamidis
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis
WO2026050334A1 (en) 2024-08-29 2026-03-05 Alexion Pharmaceuticals, Inc. Transthyretin stabilizers and methods of use thereof
EP4717261A1 (en) 2024-09-26 2026-04-01 Galenicum Health S.L.U. Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
EP4717262A1 (en) 2024-09-26 2026-04-01 Galenicum Health S.L.U. Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ATE405840T1 (de) 2002-12-19 2008-09-15 Scripps Research Inst Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
KR101125932B1 (ko) * 2006-12-06 2012-03-22 아이디유엔 파마슈티칼즈, 인코포레이티드 (3ｓ)-3-［ｎ-(ｎ'-(2-ｔｅｒｔ-부틸페닐)옥사밀)알라니닐］아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
WO2013168014A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
EP3969443B1 (en) 2019-05-16 2024-11-20 Teva Pharmaceuticals International GmbH Solid state forms of tafamidis and salts thereof
WO2021001858A1 (en) 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021152623A1 (en) 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt

Also Published As

Publication number Publication date
HRP20211834T1 (hr) 2022-03-04
PL4349406T3 (pl) 2026-03-23
MX374012B (es) 2020-07-22
RS62634B1 (sr) 2021-12-31
CN115368313A (zh) 2022-11-22
RU2692252C2 (ru) 2019-06-24
EP3977993A1 (en) 2022-04-06
JP7357525B2 (ja) 2023-10-06
TWI644902B (zh) 2018-12-21
JP2023134645A (ja) 2023-09-27
SI3977993T1 (sl) 2024-05-31
JP2016065042A (ja) 2016-04-28
PT3977993T (pt) 2024-04-01
HUE056583T2 (hu) 2022-02-28
EP4349406A2 (en) 2024-04-10
US20170273953A1 (en) 2017-09-28
KR102004059B1 (ko) 2019-07-25
EP3977993B1 (en) 2024-01-31
JP2020055832A (ja) 2020-04-09
SI4349406T1 (sl) 2026-02-27
SI3191461T1 (sl) 2022-01-31
CA2903194A1 (en) 2016-03-08
AU2015313875B2 (en) 2018-03-15
JP2022024014A (ja) 2022-02-08
BR112017003421A2 (pt) 2017-11-28
AU2015313875A1 (en) 2017-03-02
EP3191461B1 (en) 2021-11-03
BR112017003421B1 (pt) 2023-10-10
EP4349406B1 (en) 2025-12-03
RU2017107235A3 (https=) 2018-10-11
FI3977993T3 (fi) 2024-03-25
RU2017107235A (ru) 2018-10-11
ES2975633T3 (es) 2024-07-10
EP4349406A3 (en) 2024-05-22
JP2025108584A (ja) 2025-07-23
ES2901785T3 (es) 2022-03-23
NZ729011A (en) 2023-10-27
TW201613880A (en) 2016-04-16
PL3977993T3 (pl) 2024-05-06
WO2016038500A1 (en) 2016-03-17
DK4349406T3 (da) 2026-02-02
DK3977993T3 (da) 2024-02-19
LT3191461T (lt) 2021-12-10
EP3191461A1 (en) 2017-07-19
KR20170040314A (ko) 2017-04-12
PL3191461T3 (pl) 2022-02-07
SG11201700958YA (en) 2017-03-30
IL251037A0 (en) 2017-04-30
NZ766084A (en) 2023-12-22
US9770441B1 (en) 2017-09-26
ES3061774T3 (en) 2026-04-07
CY1124843T1 (el) 2022-11-25
PT4349406T (pt) 2026-02-04
MX2017002954A (es) 2017-06-15
PT3191461T (pt) 2021-12-27
HUE065233T2 (hu) 2024-05-28
CN106715405A (zh) 2017-05-24
IL251037B1 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
FI4349406T3 (fi) 6-karboksi-2-(3,5-dikloorifenyyli)-bentsoksatsolin kiteisiä kiinteitä muotoja käytettäväksi lääkkeenä
JP2016065042A5 (https=)
RU2016146119A (ru) Новый кристалл тетрациклического соединения
PH12017502246A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
AR101403A1 (es) (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares
RU2017141763A (ru) Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида
JP2014526498A5 (https=)
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
MX381000B (es) Cristales de compuesto azabicíclico.
UA118550C2 (uk) Сіль абексиностату, пов'язана з нею кристалічна форма, спосіб її отримання й фармацевтичні композиції, що її містять
HUE050847T2 (hu) A bauxit kezelési folyamata, beleértve a bauxitmaradvány kezelését szilárd termék elõállítása érdekében
PH12016502293A1 (en) Naphthyridinedione derivatives
WO2015001541A3 (en) Pharmaceutical film composition
EA202092393A1 (ru) Кристаллическое соединение оксазола
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
MY178375A (en) Polymers prepared from mevalonolactone and derivatives
WO2017214423A3 (en) Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof
MX2014010910A (es) Sales novedosas de trimebutina basadas en sulfonato.
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
JP2019526545A5 (https=)
WO2014155371A3 (en) Crystalline lenalidomide process
HRP20190961T1 (hr) Derivat tetrahidropirolo[3,4-d][1,3]tiazina kao inhibitor bace
SG11201911909UA (en) Synthesis method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use
IL291174A (en) A process for preparing a drug containing an oxane ring
HK40038449A (en) Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders